CNBC April 18, 2024
Ashley Capoot

Key Points

– 23andMe CEO Anne Wojcicki is considering a proposal to take the genetic testing company private after it has struggled to juice its stock price.

– Shares have tumbled more than 95% from their 2021 highs.

– Wojcicki is working with advisors and plans to begin speaking with possible financing sources and partners, according to an SEC filing late Wednesday.

– The company went public in 2021 via a merger with a special purpose acquisition company, which valued 23andMe at around $3.5 billion.

Anne Wojcicki, the CEO of 23andMe, is considering a proposal to take the genetic testing company private after its stock price tumbled more than 95% from its 2021 highs.

A late Wednesday filing with the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma / Biotech, Precision Medicine
Revolutionizing Primary Care: The Role of Pharmacogenomics and AI in Personalized Medicine
BioAro Announces Real Time DNA Decoding Technology
23andMe: What If …
Age of Opportunity: Artificial Intelligence and the Precision Medicine Future
Opinion: Readers respond to OTC antidepressants, personalized medicine, restoring trust in public health, and more

Share This Article